Latest Insider Transactions at Invitae Corp (NVTA)
This section provides a real-time view of insider transactions for Invitae Corp (NVTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Invitae Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Invitae Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 30
2021
|
Geoffrey Crouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+23.44%
|
-
|
|
Apr 30
2021
|
Sean E George Director |
BUY
Grant, award, or other acquisition
|
Direct |
134,200
+14.3%
|
-
|
|
Apr 30
2021
|
Robert F. Werner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,700
+31.01%
|
-
|
|
Apr 30
2021
|
Eric Aguiar Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,500
+35.34%
|
-
|
|
Apr 30
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+13.9%
|
-
|
|
Apr 30
2021
|
Christine Marie Gorjanc Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+50.0%
|
-
|
|
Apr 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.27%
|
$132,300
$36.55 P/Share
|
|
Apr 14
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
19,893
-3.24%
|
$795,720
$40.26 P/Share
|
|
Mar 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.18%
|
$154,350
$42.72 P/Share
|
|
Mar 16
2021
|
Sean E George Director |
SELL
Bona fide gift
|
Direct |
5,750
-0.84%
|
-
|
|
Mar 15
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,147
-3.75%
|
$762,174
$42.9 P/Share
|
|
Mar 15
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
27,417
-1.95%
|
$1,151,514
$42.9 P/Share
|
|
Mar 15
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Grant, award, or other acquisition
|
Direct |
5,781
-2.68%
|
$242,802
$42.9 P/Share
|
|
Mar 15
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,443
-5.46%
|
$522,606
$42.9 P/Share
|
|
Mar 12
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
16,051
-3.58%
|
$674,142
$42.9 P/Share
|
|
Mar 12
2021
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.87%
|
-
|
|
Mar 12
2021
|
Shelly D Guyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.19%
|
-
|
|
Mar 12
2021
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,159
-3.69%
|
$762,678
$42.9 P/Share
|
|
Mar 12
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.06%
|
-
|
|
Mar 12
2021
|
Sean E George Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,436
+7.0%
|
-
|
|
Mar 12
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,936
+9.86%
|
-
|
|
Mar 09
2021
|
Sean E George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,333
+3.43%
|
$23,333
$1.26 P/Share
|
|
Mar 04
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.14%
|
$135,975
$37.63 P/Share
|
|
Mar 02
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-0.45%
|
$129,000
$43.34 P/Share
|
|
Mar 01
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
5,000
-0.81%
|
$210,000
$42.94 P/Share
|
|
Feb 25
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.61%
|
$200,000
$40.33 P/Share
|
|
Feb 25
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.35%
|
$50,000
$10.23 P/Share
|
|
Feb 22
2021
|
Geoffrey Crouse Director |
SELL
Open market or private sale
|
Direct |
10,000
-18.46%
|
$480,000
$48.87 P/Share
|
|
Feb 19
2021
|
Jason W. Myers Director |
SELL
Bona fide gift
|
Direct |
310,597
-75.65%
|
-
|
|
Jan 21
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
8,675
-0.45%
|
$468,450
$54.52 P/Share
|
|
Jan 21
2021
|
Sean E George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+0.77%
|
$40,000
$8.7 P/Share
|
|
Jan 13
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,199
-0.41%
|
$214,149
$51.17 P/Share
|
|
Jan 13
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,199
+1.99%
|
$41,990
$10.94 P/Share
|
|
Jan 06
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,101
+4.29%
|
$90,909
$9.9 P/Share
|
|
Dec 30
2020
|
Sean E George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.54%
|
$10,000
$1.26 P/Share
|
|
Dec 24
2020
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,622
-1.16%
|
$181,100
$50.5 P/Share
|
|
Dec 24
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
48,971
-2.21%
|
$2,350,608
$48.85 P/Share
|
|
Dec 23
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
125,181
-5.7%
|
$6,509,412
$52.9 P/Share
|
|
Dec 22
2020
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.19%
|
$191,100
$52.85 P/Share
|
|
Dec 22
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
124,991
-4.65%
|
$6,624,523
$53.07 P/Share
|
|
Dec 21
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
99,974
-2.54%
|
$4,798,752
$48.93 P/Share
|
|
Dec 18
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
131,351
-4.82%
|
$6,304,848
$48.11 P/Share
|
|
Dec 17
2020
|
Jason W. Myers Director |
SELL
Bona fide gift
|
Direct |
300,000
-24.17%
|
-
|
|
Dec 17
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
50,692
-1.32%
|
$2,382,524
$47.38 P/Share
|
|
Dec 16
2020
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,351
-4.11%
|
$680,901
$51.0 P/Share
|
|
Dec 16
2020
|
Eric Aguiar Director |
SELL
Open market or private sale
|
Direct |
10,000
-82.0%
|
$510,000
$51.11 P/Share
|
|
Dec 16
2020
|
Eric Aguiar Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$240,000
$24.16 P/Share
|
|
Dec 16
2020
|
Jason W. Myers Director |
SELL
Open market or private sale
|
Direct |
71,869
-5.27%
|
$3,377,843
$47.32 P/Share
|
|
Dec 14
2020
|
Jason W. Myers Director |
BUY
Grant, award, or other acquisition
|
Direct |
324,399
+11.24%
|
-
|
|
Dec 14
2020
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
34,300
-2.2%
|
$1,955,100
$57.97 P/Share
|